Actively Recruiting
Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
Led by University of Arkansas · Updated on 2026-04-08
100
Participants Needed
6
Research Sites
389 weeks
Total Duration
On this page
Sponsors
U
University of Arkansas
Lead Sponsor
H
Highlands Oncology Group, PA
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a Phase II randomized, double-blind, placebo controlled, multi-site study of Candin. It is designed to show the efficacy and safety of a 7-dose regimen of Candin over a two-year period in terms of reducing cancer recurrence rate by comparing the recurrence rates between the Candin and the placebo arm. The ratio of the number of subjects who will receive Candin versus placebo will be 3:1. Up to 100 subjects will be screened until 80 subjects are eligible for injection.
CONDITIONS
Official Title
Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to provide informed consent
- Male or female 18 years of age or older
- Diagnosed with squamous cell carcinoma of the head and neck
- Completed curative therapy (surgery, radiation, chemotherapy, or immunotherapy) within 120 days prior to screening
- No evidence of disease based on clinical and radiographic evaluations
- Willing and able to comply with study requirements
You will not qualify if you...
- Positive urine pregnancy test for women of childbearing potential
- Pregnant or attempting to become pregnant during the study
- Breastfeeding or planning to breastfeed during the study period
- Allergy to Candin
- Considered by investigators to be unsuitable for study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Highlands Oncology Group, PA
Fayetteville, Arkansas, United States, 72762
Actively Recruiting
2
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States, 72205
Actively Recruiting
3
Highlands Oncology Group, PA
Rogers, Arkansas, United States, 75758
Actively Recruiting
4
Highlands Oncology Group, PA
Springdale, Arkansas, United States, 72762
Actively Recruiting
5
Perlmutter Cancer Center at NYU Langone Health
Mineola, New York, United States, 11501
Actively Recruiting
6
Perlmutter Cancer Center at NYU Langone Health
New York, New York, United States, 10016
Actively Recruiting
Research Team
M
Madison Trujillo
CONTACT
A
Aaron Holley
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here